Edition:
India

Audentes Therapeutics Inc (BOLD.OQ)

BOLD.OQ on NASDAQ Stock Exchange Global Market

37.67USD
9:10pm IST
Change (% chg)

$0.36 (+0.96%)
Prev Close
$37.31
Open
$37.15
Day's High
$37.95
Day's Low
$37.15
Volume
9,716
Avg. Vol
89,531
52-wk High
$41.80
52-wk Low
$14.00

Select another date:

Thu, Jan 4 2018

BRIEF-Audentes Announces Positive Interim Data From First Dose Cohort Of Aspiro

* AUDENTES ANNOUNCES POSITIVE INTERIM DATA FROM FIRST DOSE COHORT OF ASPIRO, A PHASE 1/2 CLINICAL TRIAL OF AT132 IN PATIENTS WITH X-LINKED MYOTUBULAR MYOPATHY

BRIEF-Audentes Therapeutics Q3 ‍loss per share $ 0.88​

* Audentes Therapeutics reports third quarter 2017 financial results and provides corporate update

BRIEF-Audentes Therapeutics to release Q3 financial results Nov. 14

* Audentes Therapeutics to release third quarter 2017 financial results and provide corporate update on Tuesday, November 14, 2017 Source text for Eikon: Further company coverage:

BRIEF-Audentes Therapeutics gets fast track designation for its muscle disorder drug

* Audentes Therapeutics announces rare pediatric disease and fast track designations for AT132 for the treatment of x-linked myotubular myopathy

BRIEF-Audentes Therapeutics commences dosing of first patient in phase 1/2 trial of AT132 for the treatment of x-linked myotubular myopathy

* Audentes Therapeutics announces dosing of first patient in ASPIRO, a phase 1/2 clinical trial of AT132 for the treatment of X-linked myotubular myopathy

BRIEF-Audentes Therapeutics files for mixed shelf offering of up to $250 mln‍​

* Audentes Therapeutics Inc files for mixed shelf offering of up to $250 million - sec filing‍​ Source text: (http://bit.ly/2fqe6ME) Further company coverage:

Select another date: